Tegaserod and other serotonergic agents: What is the evidence?

Reviews in Gastroenterological Disorders

Volumn 3, Issue SUPPL. 2, 2003, Pages

  Chey, Wiliam D ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Alosetron; Irritable bowel syndrome; Serotonin; Tegaserod

Indexed keywords

ALOSETRON; CILANSETRON; CISAPRIDE; GRANISETRON; ONDANSETRON; ORAL CONTRACEPTIVE AGENT; PLACEBO; PROTON PUMP INHIBITOR; SEROTONIN; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN AGONIST; TEGASEROD; WARFARIN;

ABDOMINAL PAIN; ADULT; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; FEMALE; FLATULENCE; GASTROINTESTINAL SECRETION; GASTROINTESTINAL TRACT FUNCTION; HEADACHE; HEART ARRHYTHMIA; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; MALE; MOTOR PERFORMANCE; PROTEIN FUNCTION; REVIEW; SENSATION;

CARBOLINES; COLONIC DISEASES, FUNCTIONAL; HUMANS; INDOLES; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0038784268     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108-2131.
2. Bearcroft CP, Perrett D, Farthing MJG. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut. 1998;42:42-46.
3. El-Salhy M, Norrgard O, Spinnell S. Abnormal colonic endocrine cells in patients with chronic idiopathic slow-transit constipation. Scand J Gastroenterol. 1999;34:1007-1011.
4. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol. 2000;95:2698-2709.
5. Mayer EA. Alosetron. Clin Perspect Gastroenterol. 1999;2:299-303.
6. 3 receptor antagonist. Aliment Pharmacol Ther. 1999;13:1149-1151.
7. Camilleri M, Northcutt AR, Kong S, et al. The Efficacy and safety of alosetron in female patients with irritable bowel syndrome: a randomized, placebo controlled study. Lancet. 2000;355:1035-1040.
8. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med. 2001;161:1733-1740.
9. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2001;96:2662-2670.
10. Jones R, Holmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female non-constipated irritable bowel syndrome patients. Aliment Pharmacol Ther. 1999;13:1419-1427.
11. Lacy BE. Tegaserod. Clin Perspect Gastroenterol. 2002;5:251-255.
12. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther. 2001;15:777-789.
13. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, and constipation. Aliment Pharmacol Ther. 2001;15:1655-1666.
14. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther. 2001;15(3):277-289.
15. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002;16:1877-1888.
16. Kellow J, Lee O, Chang F, et al. Tegaserod is an effective therapy for non-diarrheal IBS in Asian-Pacific population [abstract]. Gut. In press.
17. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97:S7-S26.
18. Schoenfeld P, Chey W, Drossman D, et al. Effectiveness and safety of tegaserod in the treatment of irritable bowel syndrome: a meta-analysis of randomized controlled trials. Gastroenterology. 2002;112:A1486.
19. Tougas G, Snape Jr. WJ, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2002;16:1701-1708.
20. Morganroth J, Rüegg PC, Dunger-Baldauf C, et al. Tegaserod, a 5-Hydroxytryptamine type 4 receptor partial agonist, is devoid of electro-cardiographic effects. Am J Gastroenterol. 2002;97:2321-2337.
21. Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg. 2000;87:1658-1663.
22. Olden K, Chey WD, Boyle J, et al. Health related quality of life in irritable bowel syndrome: a community based study. Gastroenterology. 2001;120:A634.